HTFL (Heartflow, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by HTFL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | Campbell Rogers | Chief Medical Officer | MIXED | — | — |
| 2026-09-18 | Vikram Verghese | Chief Financial Officer | Sell | — | — |
| 2026-09-15 | Vikram Verghese | Chief Financial Officer | Sell | — | — |
| 2026-09-14 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-09-10 | Vikram Verghese | Chief Financial Officer | Sell | — | — |
| 2026-09-04 | Vikram Verghese | Chief Financial Officer | Sell | — | — |
| 2026-08-25 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-08-20 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-08-19 | Campbell Rogers | Chief Medical Officer | MIXED | — | — |
| 2026-08-18 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-08-12 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-08-10 | Vikram Verghese | Chief Financial Officer | MIXED | — | — |
| 2026-08-10 | John C.M. Farquhar | Chief Executive Officer | F | — | — |
| 2026-08-10 | Marie L. Jones | Chief Accounting Officer | MIXED | — | — |
| 2026-08-10 | Campbell Rogers | Chief Medical Officer | F | — | — |
| 2026-07-31 | John C.M. Farquhar | Chief Executive Officer | M | — | — |
| 2026-07-28 | Jeffrey C Lightcap | Director | M | — | — |
| 2026-07-28 | Vikram Verghese | Chief Financial Officer | M | — | — |
| 2026-07-24 | TIMOTHY C BARABE | Director | M | — | — |
| 2026-07-23 | Vikram Verghese | Chief Financial Officer | M | — | — |
| 2026-07-20 | TIMOTHY C BARABE | Director | M | — | — |
| 2026-07-17 | Campbell Rogers | Chief Medical Officer | MIXED | — | — |
| 2026-07-13 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-07-10 | WILLIAM C WELDON | Director | M | — | — |
| 2026-06-26 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-06-18 | TIMOTHY C BARABE | Director | A | — | — |
| 2026-06-18 | Julie A Cullivan | Director | A | — | — |
| 2026-06-18 | Casey M Tansey | Director | A | — | — |
| 2026-06-18 | Jeffrey C Lightcap | Director | A | — | — |
| 2026-06-18 | Wayne Joseph Riley | Director | A | — | — |
| 2026-06-18 | WILLIAM C WELDON | Director | A | — | — |
| 2026-06-17 | Campbell Rogers | Chief Medical Officer | M | — | — |
| 2026-06-12 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-05-20 | Campbell Rogers | Chief Medical Officer | MIXED | — | — |
| 2026-05-13 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-05-08 | Marie L. Jones | Chief Accounting Officer | F | — | — |
| 2026-05-08 | John C.M. Farquhar | Chief Executive Officer | F | — | — |
| 2026-05-08 | Campbell Rogers | Chief Medical Officer | F | — | — |
| 2026-05-08 | Vikram Verghese | Chief Financial Officer | F | — | — |
| 2026-04-14 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-04-03 | Campbell Rogers | Chief Medical Officer | MIXED | — | — |
| 2026-03-26 | HealthCor Partners Management LP | Director | J | — | — |
| 2026-03-26 | Jeffrey C Lightcap | Director | J | — | — |
| 2026-03-23 | Campbell Rogers | Chief Medical Officer | MIXED | — | — |
| 2026-03-20 | John C.M. Farquhar | Chief Executive Officer | Sell | — | — |
| 2026-03-12 | TIMOTHY C BARABE | Director | M | — | — |
| 2026-03-12 | John C.M. Farquhar | Chief Executive Officer | MIXED | — | — |
| 2026-03-06 | Julie A Cullivan | Director | Sell | — | — |
| 2026-02-19 | TIMOTHY C BARABE | Director | M | — | — |
| 2026-02-17 | Campbell Rogers | Chief Medical Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 12,014,234 | — |
| — | 10%+ Owner | 10,448,158 | — |
| — | Director | 3,089,206 | — |
| — | Director | 1,542,620 | — |
| — | 10%+ Owner | 833,075 | — |
| — | Chief Executive Officer | 325,804 | — |
| — | Director | 209,685 | — |
| — | Director | 188,231 | — |
| — | Chief Financial Officer | 171,949 | — |
| — | Chief Medical Officer | 102,571 | — |
| — | Chief Accounting Officer | 32,258 | — |
| — | Director | 27,291 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HTFL quote page; the site-wide leaderboard is on the insider transactions hub.